Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer

Description

To goal of this clinical trial is to quantify the dose-response effects of aerobic exercise training compared to attention control on chemotherapy relative dose intensity in colon cancer survivors.

Conditions

Colonic Neoplasms

Talk to us

Study Overview

On this page

Study Details

Study overview

To goal of this clinical trial is to quantify the dose-response effects of aerobic exercise training compared to attention control on chemotherapy relative dose intensity in colon cancer survivors.

Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer

Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer

Condition
Colonic Neoplasms
Intervention / Treatment

-

Contacts and Locations

Oakland

Kaiser Permanente Northern California, Oakland, California, United States, 94612

Baton Rouge

Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States, 70808

Boston

Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 02215

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age ≥18 years
  • * Histologically confirmed stage II or III colon cancer
  • * Completed surgical resection with curative intent
  • * Plan to initiate chemotherapy
  • * Engage in \<60 minutes per week of moderate- to vigorous-intensity structured aerobic exercise
  • * No planned major surgery during the study period
  • * Readiness to exercise, as determined by a modified version of the Physical Activity Readiness Questionnaire
  • * Can walk 400 meters
  • * Can read and speak English
  • * Ability to provide written informed consent
  • * Provide written approval by qualified healthcare professional
  • * Willing to be randomized
  • * Evidence of metastatic colon cancer
  • * Concurrently actively treated other (non-colon) cancer
  • * Currently pregnant, breastfeeding, or planning to become pregnant within the next 24 weeks
  • * Currently participating in another study with competing outcomes
  • * Any other condition that, in the opinion of the investigator, would preclude participation or successful compliance with the protocol
  • * Any other situation that, in the opinion of the investigator, would negatively impact subject safety or successful compliance with the protocol

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Pennington Biomedical Research Center,

Justin C. Brown, Ph.D., PRINCIPAL_INVESTIGATOR, Pennington Biomedical Research Center

Jeffrey A. Meyerhardt, M.D., M.P.H., PRINCIPAL_INVESTIGATOR, Dana-Farber Cancer Institute

Bette J. Caan, Dr.P.H., PRINCIPAL_INVESTIGATOR, Kaiser Permanente

Study Record Dates

2027-05